Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of GSK3335065 in Healthy Adults
NCT03245619Phase 1Terminated
- Sponsor
- GSK
- Start
- Aug 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3335065 in acute pancreatitis (AP) (8 arms), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Hematological Parameters of Potential Clinical Importance and 4 more. Started Aug 2017; status: terminated.
02
Drugs
GSK3335065
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on NCT03245619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245619.